Merck KGaA Announces Collaboration And Investment In Three China Sectors
Merck KGaA, Darmstadt, Germany, today signed an agreement with Alibaba Health, opened a technology center for its OLED customers in Shanghai, and announced the participation of Tongji University, Shanghai, China, in its CRISPR Core Partnership Program. The new collaboration with Chinese Internet healthcare company Alibaba Health, which was announced today, aims to provide Chinese patients…
Merck Presents Promising Phase II Trial Results for OA Drug
Merck KGaA May Sell Its Consumer Health Business
Merck KGaA Divests Biosimilars Business to Fresenius Kabi
Merck KGaA Signs Deal for Development of Plaque Psoriasis Therapy
Merck KGaA, Darmstadt, Germany advances R&D strategy through unique development model with Avillion for anti IL-17 A/F Nanobody. Merck KGaA, Darmstadt, Germany announced a development agreement with Avillion, a U.K.-based company focused on increasing R&D output through innovative models, for anti IL-17 A/F Nanobody. Merck KGaA, Darmstadt, Germany’s anti IL-17 A/F Nanobody is an investigational therapy which has completed…
Merck KGaA Reports Record Sales and Profit Growth
Healthcare and Life Science drive Group organic sales growth in the fourth quarter In the fourth quarter of 2016, Group sales rose by 10.6% to € 3.8 billion (Q4 2015: € 3.5 billion). This was driven not only by organic growth attributable to Healthcare and Life Science, but also by strong acquisition-related sales growth from…
